Iyan
3 sources • 2 verified points

أركوتيس تعلن نتائج الربع الثالث 2026 وتحديث الأعمال

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026 ...

AI-written summary of 3 sources; every verified point is backed by a verbatim quote. How Iyan works

SourcesAOLBioSpaceAOLYahoo Finance
Follow this development in Iyan

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms